RBC Capital analyst Keith Mackey reiterates Shawcor (TSX:SCL) with a Outperform and maintains C$15 price target.
Sigilon Therapeutics Q3 EPS $(0.27) Up From $(0.63) YoY, Sales $4.25M Up From $1.95M YoY
Sigilon Therapeutics (NASDAQ:SGTX) reported quarterly losses of $(0.27) per share. This is a 57.14 percent increase over losses of $(0.63) per share from the same period last year. The company reported $4.25 million in
